Time and Motion Study for Rituximab Sc vs Iv in Colombian Patients With Non-Hodgkin Lymphoma

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.03.1200
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2016English

Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma

Haematologica
Hematology
2015English

Statin Use and Prognosis in 12,865 Non-Hodgkin Lymphoma Patients Treated in the Rituximab-Era

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Rituximab and FAB/LMB 96 Chemotherapy in Children With Stage III/IV B-Cell Non-Hodgkin Lymphoma: A Children’s Oncology Group Report

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2012English

Subcutaneous Rituximab in B-Cell Non-Hodgkin Lymphoma: A Single-Center Experience

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-Cell Non-Hodgkin Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2012English

Non-Hodgkin Lymphoma

2020English

Study of Gene Polymorphisms as Predictors of Treatment Efficacy and Toxicity in Patients With Indolent Non-Hodgkin Lymphomas and Mantle Cell Lymphoma Receiving Bendamustine and Rituximab

British Journal of Haematology
Hematology
2018English

Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy